Declining sales of cancer drug Avastin, health care reform and a strong Swiss franc pushed down first-quarter revenue for Genentech Inc. parent Roche Holding AG by 9 percent, the company said.
Avastin sales, measured in francs, dropped 15 percent, Roche said. Overall, Roche sales fell 9 percent to 11.1 billion francs, or $12.4 billion.
No comments:
Post a Comment